Physician profile
Fahed Elchami
NPI 1013300839
$1,341.65
in general payments reported to CMS, 2019-2025
11 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.77 · 2020: $382 · 2022: $60.99 · 2023: $550 · 2024: $224 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $544.22 | 2020-2023 | |
| Kerecis Limited | $288.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Stryker Corporation | $164.51 | 2024 | Alphavent, Iconix |
| Ferring Pharmaceuticals INC. | $156.13 | 2023-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $43.23 | 2019-2025 | Motoband |
| Kowa Pharmaceuticals America, INC. | $41.71 | 2022 | |
| Orthofix Medical, INC. | $28.50 | 2023 | Physio-Stim, Spinal-Stim |
| Integra Lifesciences Corporation | $27.38 | 2020 | |
| Organogenesis INC. | $19.28 | 2022 | |
| Bioventus LLC | $15.28 | 2024 | Gelsyn-3 |
| Pacira Pharmaceuticals Incorporated | $12.97 | 2023 | Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahed Elchami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.